Unadjusted | IPWRA-Adjusted | ||||
---|---|---|---|---|---|
PARPi Monotherapy (n = 38) | Chemotherapya (n = 58) | P Values | PARPi Monotherapy (n = 38) | Chemotherapya (n = 58) | |
Mean age at therapy initiation, years | 50.7 | 51.3 | 0.829† | 50.2 | 50.5 |
Female sex, % | 100 | 100 | 1.000‡ | 100 | 100 |
White race, % | 86.8 | 93.1 | 0.476‡ | 91.9 | 85.8 |
Premenopausal, % | 44.7 | 41.4 | 0.834‡ | 43.7 | 43.7 |
HR+/HER2− status, % | 31.6 | 36.2 | 0.667‡ | 34.5 | 38.4 |
Currently known to be working full/part time, % | 28.9 | 24.1 | 0.640‡ | 30.4 | 25.2 |
Charlson Comorbidities Index, mean | 6.2 | 7.5 | 0.017† | 7.1 | 7.1 |
Baseline toxicities,b % | |||||
Constitutional | 47.4 | 36.2 | 0.296 ‡ | 29.6 | 33.9 |
Pulmonary | 31.6 | 19.0 | 0.221 ‡ | 20.1 | 19.3 |
Gastrointestinal | 26.3 | 15.5 | 0.204 ‡ | 14.7 | 15.4 |
Dermatologic | 36.8 | 8.6 | 0.001 ‡ | 19.2 | 15.7 |
Neurologic | 18.4 | 1.7 | 0.006 ‡ | 8.5 | 6.1 |
Psychological | 18.4 | 5.2 | 0.047 ‡ | 9.9 | 9.4 |
Physical | 63.2 | 29.3 | 0.002 ‡ | 34.4 | 38.8 |
Pain | 34.2 | 20.7 | 0.159 ‡ | 23.4 | 23.8 |
ECOG performance status at treatment initiation, mean | 0.7 | 0.8 | 0.460 † | 0.75 | 0.80 |
Stage IV at current treatment initiation, % | 65.8 | 89.7 | 0.008 ‡ | 82.3 | 83.0 |
Line of current treatment, mean | 1.9 | 1.4 | 0.002† | 1.6 | 1.6 |